Page 101 - GPD-2-1

Gene & Protein in Disease SCN7A is a protective factor in LUAD

A

B

Figure 4. Messenger RNA (mRNA) transcription and expression of SCN7A protein in lung adenocarcinoma (LUAD). (A) Trend in the expression of
SNC7A mRNA in LUAD among different stages, people of different age, and between gender; and the relationship between SNC7A expression and the
overall survival (OS) of LUAD patients. (B) SCN7A protein level in lung cancer tissues and normal tissues from the Human Protein Atlas database.

Figure 5. Somatic mutation landscape of SCN7A in lung adenocarcinoma (LUAD) cells.

To explore the correlation between SCN7A and immune tissues, consistent with the prognostic results. Thus, SCN7A
checkpoint therapy in LUAD, we assessed the correlation is a potential biomarker for LUAD prognosis prediction.
between SCN7A expression and immune checkpoints.
Cytotoxic T-lymphocyte associated protein 4 (CTLA4), 3.7. Upstream non-coding RNAs of SCN7A
hepatitis A virus cellular receptor 2 (HAVCR2), programmed We searched through miRGator v3.0 database containing
cell death 1 ligand 2 (PD-L2), and T cell immunoreceptor data for 25 miRNAs to identify the upstream regulatory
with Ig and ITIM domains (TIGIT) expressions were mechanism of SCN7A in LUAD. Given how miRNAs
positively correlated to SCN7A expression, whereas LAG3 regulate gene expression, miRNAs should be negatively
expression showed a negative correlation (Figure 7C). correlated with SCN7A. Thus, we selected 15 miRNAs
These results suggest a strong correlation between that were negatively correlated with SCN7A for further
SCN7A expression and immune cell infiltration to LUAD investigation. The expression of these miRNAs in LUAD

Volume 2 Issue 1 (2023) 6 https://doi.org/10.36922/gpd.363